Stem cell transplantation outcomes in lymphoblastic lymphoma

作者：Brammer Jonathan E^*; Khouri Issa; Marin David; Ledesma Celina; Rondon Gabriela; Ciurea Stefan O; Nieto Yago; Champlin Richard E; Hosing Chitra; Kebriaei Partow

来源：Leukemia and Lymphoma, 2017, 58(2): 366-371.

DOI：10.1080/10428194.2016.1193860

• Allogeneic stem cell transplantation
• autologous stem cell transplantation
• clinical results
• lymphoblastic lymphoma

Lymphoblastic lymphoma (LBL) is an aggressive lymphoma pathologically similar to lymphoblastic leukemia, but primarily presents with nodal or extra-medullary involvement. The aim of this study is to describe outcomes of patients undergoing stem cell transplantation (SCT) for LBL compared to historical data. Thirty-nine patients, of which 54% lacked complete remission (CR), received SCT for LBL between 1990 and 2015; 31 allogeneic and eight autologous. Overall survival (OS) and progression free survival (PFS) at three years for the entire cohort was 41%, the cumulative incidence (CI) of non-relapse mortality (NRM) was 18% at one year, and CI relapse mortality was 28% at one-year and 36% at three years; results similar to historical reports. On multivariate analysis, the use of total-body irradiation (TBI) based conditioning and transplantation in CR were independently predictive of OS and PFS. For patients requiring SCT for LBL, CR and TBI-based conditioning prior to allogeneic SCT may provide improved disease control.

• 出版日期2017-2